LENZ Therapeutics (LENZ) CFO buys 7,500 shares of stock

Rhea-AI Filing Summary

LENZ Therapeutics, Inc. Chief Financial Officer Daniel R. Chevallard reported an open-market purchase of 7,500 shares of common stock at $8.57 per share. Following this transaction, his direct holdings increased to 12,886 shares of LENZ common stock.

Insider Trade Summary

Net Buyer: 7,500 shares ($64,275)

Net Buy 1 txn

Insider Chevallard Daniel R.

Role Chief Financial Officer

Bought 7,500 shs ($64K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	7,500	$8.57	$64K

Holdings After Transaction: Common Stock — 12,886 shares (Direct)

Footnotes (1)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chevallard Daniel R.

(Last) (First) (Middle)

C/O LENZ THERAPEUTICS, INC.

201 LOMAS SANTA FE DRIVE, SUITE 300

(Street)

SOLANA BEACH CALIFORNIA 92075

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LENZ Therapeutics, Inc. [ LENZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/27/2026		P		7,500	A	$8.57	12,886	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Daniel R. Chevallard	03/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did LENZ CFO Daniel R. Chevallard report in this Form 4?

Daniel R. Chevallard, CFO of LENZ Therapeutics, reported buying 7,500 shares of common stock in an open-market purchase at $8.57 per share, increasing his direct ownership to 12,886 shares after the transaction.

How many LENZ Therapeutics (LENZ) shares did the CFO buy and at what price?

The CFO bought 7,500 shares of LENZ Therapeutics common stock at a price of $8.57 per share. This open-market purchase is classified under transaction code P, indicating a standard purchase in the market or a private transaction.

What is Daniel R. Chevallard’s total LENZ Therapeutics shareholding after this Form 4 transaction?

After the reported transaction, Daniel R. Chevallard directly owns 12,886 shares of LENZ Therapeutics common stock. This total reflects his holdings immediately following the open-market purchase of 7,500 additional shares disclosed in the Form 4 filing.

How is the LENZ Therapeutics CFO’s transaction classified in the Form 4 data?

The transaction is classified as a non-derivative open-market purchase of common stock, coded P. The filing labels the direction as a buy, confirming it as an acquisition of 7,500 shares rather than a sale or derivative-related transaction.

Does the LENZ Therapeutics (LENZ) Form 4 show any derivative securities for the CFO?

The Form 4 data show no derivative securities for the CFO in this filing. The derivativeSummary is empty, indicating only a common stock purchase was reported, with no options, warrants, or other derivative transactions disclosed alongside this trade.